Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc > Lvl 2 Data

<< Previous

Bullboard Posts

Next >>

Post by theNormon May 08, 2020 10:58am

115 Views

Post# 31003064

Lvl 2 Data

Last:

0.395

Change:

0.000

Volume:

479,759

Last Trade:

10:56

Level ll Quote
Bid			Ask
Price	Total Size	# of Orders	Price	Total Size	# of Orders

$0.39	22500	7	$0.40	94000	4
$0.385	51000	13	$0.405	195000	6
$0.38	50000	16	$0.41	122500	11
$0.375	23500	5	$0.415	14000	3
$0.37	32000	5	$0.42	70500	7
$0.365	30500	2	$0.425	67500	3
$0.36	42500	7	$0.43	25000	2
$0.355	20500	3	$0.435	1000	1
$0.35	82500	16	$0.44	6500	2
$0.345	7500	2	$0.45	22500	2